Evidence map›Paper›PMID 37060495›Full record

ReviewAngiogenesis2023

Pathological angiogenesis: mechanisms and therapeutic strategies.

Andrew C Dudley, Arjan W Griffioen

Open access · hybridAbstract readReview
In one paragraph

Review in Angiogenesis, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 285 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
285citing papers in PubMed, 1 pooled it
64.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

285 citing papers in PubMed, 1 synthesis or guideline pooled it, 411 citations in OpenAlex.

  1. Inflammatory cytokines are associated with stroke and risk factors of cerebrovascular diseases: a Mendelian randomization study.Mammalian genome : official journal of the International Mammalian Genome Society · 2025
    Pooled it
  2. World journal of diabetes · 2025
    Trial
  3. Article
  4. Article
  5. Molecular Mechanisms Governing Vascular Function in Heart Failure.Arteriosclerosis, thrombosis, and vascular biology · 2026
    Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Role of ZEB1 in angiogenesis and therapeutic potential (Review).International journal of molecular medicine · 2026
    Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. Review
  18. Article
  19. Review
  20. Article

225 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 2 countries.

Andrew C DudleyDepartment of Microbiology, Immunology and Cancer Biology, The University of Virginia, Charlottesville, VA, 22908, USA. acd2g@virginia.edu.
Arjan W GriffioenAngiogenesis Laboratory, Department of Medical Oncology, Amsterdam UMC, Cancer Center Amsterdam, Amsterdam, The Netherlands. a.griffioen@amsterdamumc.nl.
Amsterdam University Medical Centers · NLUniversity of Virginia · US

Funding

Targeting the vasculature to enhance anti-tumor immunityR01CA177875 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Andrew Carl Dudley · 2014 to 2026
$4.5M
Gasdermin E-mediated pyroptosis in promoting antitumor immunity and cancer treatmentK99CA255841 · NCI · BOSTON CHILDREN'S HOSPITAL · PI ZHANG, YING · 2021 to 2022
$224k
NCI NIH HHS K99 CA255841NCI NIH HHS R01 CA177875
6 · The paper itself

Abstract

In multicellular organisms, angiogenesis, the formation of new blood vessels from pre-existing ones, is an essential process for growth and development. Different mechanisms such as vasculogenesis, sprouting, intussusceptive, and coalescent angiogenesis, as well as vessel co-option, vasculogenic mimicry and lymphangiogenesis, underlie the formation of new vasculature. In many pathological conditions, such as cancer, atherosclerosis, arthritis, psoriasis, endometriosis, obesity and SARS-CoV-2(COVID-19), developmental angiogenic processes are recapitulated, but are often done so without the normal feedback mechanisms that regulate the ordinary spatial and temporal patterns of blood vessel formation. Thus, pathological angiogenesis presents new challenges yet new opportunities for the design of vascular-directed therapies. Here, we provide an overview of recent insights into blood vessel development and highlight novel therapeutic strategies that promote or inhibit the process of angiogenesis to stabilize, reverse, or even halt disease progression. In our review, we will also explore several additional aspects (the angiogenic switch, hypoxia, angiocrine signals, endothelial plasticity, vessel normalization, and endothelial cell anergy) that operate in parallel to canonical angiogenesis mechanisms and speculate how these processes may also be targeted with anti-angiogenic or vascular-directed therapies.

Indexed as

COVID-19NeoplasmsAngiogenesis InhibitorsEndothelial CellsFemaleHumansNeovascularization, PathologicSARS-CoV-2Angiogenesis InhibitorsAngiogenesisAnti-angiogenesisEndothelial cellsImmunotherapyVascular biologyVascular targeting

Identifiers

PMID37060495
PMCPMC10105163
OpenAlexW4365810819

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.